Article
Pharmacology & Pharmacy
Evelien Moorkens, Brian Godman, Isabelle Huys, Iris Hoxha, Admir Malaj, Simon Keuerleber, Silvia Stockinger, Sarah Moertenhuber, Maria Dimitrova, Konstantin Tachkov, Luka Voncina, Vera Vlahovic Palcevski, Gnosia Achniotou, Juraj Slaby, Leona Popelkova, Katerina Kohoutova, Dorthe Bartels, Ott Laius, Jaana E. Martikainen, Gisbert W. Selke, Vasileios Kourafalos, Einar Magnusson, Rannveig Einarsdottir, Roisin Adams, Roberta Joppi, Eleonora Allocati, Arianit Jakupi, Anita Viksna, Ieva Greiciute-Kuprijanov, Patricia Vella Bonanno, Vincent Suttorp, Oyvind Melien, Robert Plisko, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Furst, Corinne Zara, Vanda Markovic-Pekovic, Natasa Grubisa, Gustaf Befrits, Robert Puckett, Arnold G. Vulto
Summary: This study surveyed the pricing changes and policy measures in European countries after the entry of adalimumab biosimilars. Results showed that while some countries adopted specific policies for adalimumab, they are not widespread despite adalimumab being the highest selling product globally. Countries with biosimilars on the market seemed to have competition lowering prices, with reported discounts varying widely between countries.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Immunology
XiaoQin Lu, Rui Hu, Lin Peng, MengSi Liu, Zhen Sun
Summary: "Seven biosimilars of adalimumab approved for rheumatoid arthritis treatment by FDA and/or EMA have shown similar efficacy, safety, and immunogenicity to adalimumab, with switching trials indicating no significant impact on these factors."
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Chemistry, Medicinal
Xin Zhou, Zhuo Chen, Xinling Bi
Summary: Biologic drugs have revolutionized the treatment of psoriasis and rheumatological diseases, with biosimilar agents showing similar structure and function to originator products at a considerably lower cost. Approvals of adalimumab biosimilars by US FDA and EMA have expanded access to biologic therapies, with guidance on interchangeability and real-life practices still evolving.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Pharmacology & Pharmacy
Eleonora Allocati, Brian Godman, Marco Gobbi, Silvio Garattini, Rita Banzi
Summary: This study summarizes evidence on switching between biosimilars, suggesting no significant concerns in practice. Monitoring the use of biosimilars can support clinical decision-making.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Zvonimir Petric, Joao Goncalves, Paulo Paixao
Summary: Monoclonal antibodies have revolutionized the treatment of chronic inflammatory diseases, but they face challenges related to their immunogenicity, effectiveness, and safety. Biosimilars have emerged as a cost-effective alternative and have been shown to be as safe and effective as the originator drugs in treating IBD patients.
Article
Multidisciplinary Sciences
Martin Wasserbauer, Stepan Hlava, Jiri Drabek, Jan Stovicek, Petra Minarikova, Lenka Nedbalova, Tomas Drasar, Zdena Zadorova, Jiri Dolina, Stefan Konecny, Vladimir Kojecky, Jana Kozeluhova, Pavlina Cernikova, Dita Pichlerova, Barbora Kucerova, Stepan Coufal, Radan Keil
Summary: This prospective observational study demonstrated the effectiveness of adalimumab biosimilars FKB327 and GP2017 in patients with IBD.
Article
Environmental Sciences
Piergiuseppe Morone, Idiano D'Adamo, Mattia Cianfroni
Summary: The use of renewable biological resources to produce food, materials, and energy is a potential solution for implementing the green transition. This study investigates the bioeconomy sectors in 28 European countries using a socio-economic indicator and provides useful data for stakeholders. The results show Ireland outperforming the Netherlands and Denmark in all sectors, particularly in manufacturing and bio-energy.
ENVIRONMENTAL RESEARCH LETTERS
(2022)
Article
Biotechnology & Applied Microbiology
Emilia Anderson, Karen Waller, Aravind Gokul Tamilarasan, Huiyu Lin, Sudarshan Paramsothy, Rupert W. Leong
Summary: This article compares and contrasts originator and biosimilar adalimumab agents, identifying key differences such as product formulation, dosages available, delivery devices, physician support, patient support, and the supply of other biosimilar products by the company. Therefore, the choice of agent should be individualized to the needs of the patient and the healthcare service.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Article
Oncology
Victoria Nikitina, Greta Santi Laurini, Nicola Montanaro, Domenico Motola
Summary: Biosimilar drugs are widely used in clinical fields, but there is skepticism about their safety compared to reference products. This study used real-world clinical data to compare the safety of biosimilars and reference products, and the results showed that they are comparable. This supports the wider use of biosimilars, allowing more patients to receive effective treatments and saving healthcare resources.
Review
Rheumatology
Tom W. J. Huizinga, Yoshifumi Torii, Rafael Muniz
Summary: Biologic disease-modifying antirheumatic drugs (bDMARDs) have significantly improved outcomes for patients with rheumatoid arthritis (RA), but many patients lack access to these treatments. Biosimilars offer a cost-effective alternative and studies have shown that they are highly similar to the reference products in terms of efficacy and safety for the treatment of RA and other chronic immune-mediated inflammatory diseases.
RHEUMATOLOGY AND THERAPY
(2021)
Review
Environmental Sciences
Piotr Kanarek, Tomasz Bogiel, Barbara Breza-Boruta
Summary: There has been an increase in the number of legionellosis cases in the European Union and the European Economic Area in recent years, with a significant rise from 6947 reports in 2015 to 11,298 in 2019. This is concerning because Legionella, a group of bacteria found in various aquatic systems, poses a serious threat to human health, with more than 20 species capable of causing legionellosis. Understanding the Legionella habitat is crucial for effective control of this pathogen. This paper provides an overview of Legionella environments in Europe, both natural and anthropogenic, and discusses the role of Legionella spp. in nosocomial infections, which can be fatal for vulnerable populations.
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
(2022)
Article
Chemistry, Analytical
Silvia Millan-Martin, Craig Jakes, Sara Carillo, Jonathan Bones
Summary: Adalimumab, the first fully human monoclonal antibody approved by FDA, is the most profitable drug in the world. The expiration of patent protection opens up the market for adalimumab biosimilars, which have the potential to lower costs and increase patient accessibility. This study uses a multi-attribute method to analyze the similarity of different adalimumab biosimilars.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
(2023)
Review
Psychiatry
Riccardo De Giorgi, Nicola Rizzo Pesci, Alice Quinton, Franco De Crescenzo, Philip J. Cowen, Catherine J. Harmer
Summary: The research on the effects of statins on depression shows that most studies support their positive impact on reducing the occurrence and severity of depression, with a few showing no significant effects, and a minority indicating negative effects. Further clinical studies are needed to explore the potential role of statins in treating depression, especially in specific subgroups of patients identified through pre-treatment assessments of inflammatory and lipid profiles.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Rheumatology
Hafsah Nabi, Stylianos Georgiadis, Anne Gitte Loft, Oliver Hendricks, Dorte Vendelbo Jensen, Marlene Andersen, Stavros Chrysidis, Ada Colic, Kamilla Danebod, Mohamad Redha Hussein, Maren Hogberget Kalisz, Salome Kristensen, Niels Lomborg, Natalia Manilo, Heidi Lausten Munk, Jens Kristian Pedersen, Johnny Lillelund Raun, Frank Mehnert, Niels Steen Krogh, Merete Lund Hetland, Bente Glintborg
Summary: In this observational cohort study, the comparative effectiveness of GP2017 versus SB5 in patients with rheumatoid arthritis (RA)/psoriatic arthritis (PsA)/axial spondyloarthritis (AxSpA) following a mandatory switch from the originator was assessed. GP2017 showed lower withdrawal risk, higher remission rate, and lower withdrawal rate than SB5 over 1 year.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Review
Health Care Sciences & Services
Vered Abitbol, Salim Benkhalifa, Caroline Habauzit, Hubert Marotte
Summary: This article explores the characteristics of various adalimumab biosimilars to help clinicians navigate the various options available across Europe and the USA. Effective patient-physician communication is also emphasized to nurture realistic patient expectations and minimize potential nocebo effects when prescribing biosimilars.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
(2023)
Article
Gastroenterology & Hepatology
James J. Ashton, Guo Cheng, Imogen S. Stafford, Melina Kellermann, Eleanor G. Seaby, J. R. Fraser Cummings, Tracy A. F. Coelho, Akshay Batra, Nadeem A. Afzal, R. Mark Beattie, Sarah Ennis
Summary: CD is highly heterogenous and may have stricturing behavior. A NOD2 genomic biomarker can predict stricturing risk, with prognostic power improved in pediatric-onset CD. Implementation into clinical setting can help personalize management.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Dermatology
Angela L. Bosma, Annelie H. Musters, Manja Bloem, Louise A. A. Gerbens, Maritza A. Middelkamp-Hup, Eva Haufe, Jochen Schmitt, Sebastien Barbarot, Julien Seneschal, Delphine Staumont-Salle, Emma K. Johansson, Maria Bradley, Laura B. von Kobyletzki, Ida Vittrup, Iben Frier Ruge, Jacob P. Thyssen, Christian Vestergaard, Marina de Vega, Ignacio Garcia-Doval, Andrea Chiricozzi, Luca Stingeni, Piergiacomo Calzavara-Pinton, Michael R. Ardern-Jones, Nick J. Reynolds, Carsten Flohr, Phyllis Spuls
Summary: The TREAT Registry Taskforce is a collaborative network collecting real-world data on atopic eczema patients. This study provides an overview of the eight established TREAT registries and examines the overlap and pooling ability of their datasets. The results show that pooled analyses can be performed on multiple important domain items, enabling future comparative analyses.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Review
Allergy
Ying Xin Teo, Peter Simon Friedmann, Marta Ewa Polak, Michael Roger Ardern-Jones
Summary: Skin tests, particularly patch tests and intradermal tests, have been reported as valuable tools in assessing drug causality in DRESS. However, the heterogeneity in methodology, results analysis, and reporting of cohorts make it impossible to determine the sensitivity and specificity of the published literature. International collaboration is needed to harmonize the methodology and reporting measures in larger hypersensitivity testing studies.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2023)
Letter
Dermatology
Michael R. Ardern-Jones, Emily E. Buchanan, Samba Njungu, Daniel O'Driscoll
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Kalum Clayton, Daniel J. Holbrook, Andres Vallejo, Gemma Porter, Sofia Sirvent, James Davies, Jenny Pople, Fei Ling Lim, Myron Christodoulides, Marta E. Polak, Michael R. Ardern-Jones
Summary: This study explores the interaction between keratinocyte proliferation and differentiation status and the skin microbiome. It is found that Staphylococcus epidermidis is significantly associated with the human epidermis and can induce epidermal inflammation and antimicrobial responses. Furthermore, it activates the expression of inflammatory mediators in other epidermal immune cell populations. Understanding the mechanisms of bacterial sensing-triggered inflammatory responses will further our understanding of microbiome dysbiosis and inflammatory skin diseases.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Multidisciplinary Sciences
Michael R. Ardern-Jones, Hang T. T. Phan, Florina Borca, Matt Stammers, James Batchelor, Isabel C. Reading, Sophie V. Fletcher, Trevor Smith, Andrew S. Duncombe
Summary: Blood markers can predict mortality in COVID-19 patients, and early dexamethasone treatment can reduce mortality in high-risk patients but not in low-risk patients. The risk-benefit of dexamethasone should be carefully assessed in COVID-19 cases, and alternative approaches should be considered for low-risk patients.
Article
Pharmacology & Pharmacy
Geert D'Haens, Walter Reinisch, Stefan Schreiber, Fraser Cummings, Peter M. M. Irving, Byong Duk Ye, Dong-Hyeon Kim, SangWook Yoon, Shomron Ben-Horin
Summary: This study compared the pharmacokinetics, efficacy, and immunogenicity of subcutaneous infliximab monotherapy and combotherapy in biologic-naive patients with inflammatory bowel disease. The results showed comparable outcomes between the two treatment groups.
CLINICAL DRUG INVESTIGATION
(2023)
Article
Dermatology
Carsten Flohr, Michael J. Cork, Michael R. Ardern-Jones, Lawrence F. Eichenfield, Sebastien Barbarot, Claire Feeney, Ricardo Rojo, Irina Lazariciu, John Nesnas
Summary: The study evaluated the response to treatment with continuous/reduced-dose abrocitinib or withdrawal and reintroduction after flare in adolescents and adults with atopic dermatitis. It found that abrocitinib was effective in preventing flare in both age groups, with no significant difference in response between adolescents and adults.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Article
Infectious Diseases
Nathan J. Brendish, Kate R. Beard, Ahalya K. Malachira, Alex R. Tanner, Langizya Sanga-Nyirongo, Markus Gwiggner, J. R. Fraser Cummings, Helen E. Moyses, Tristan W. Clark
Summary: This study aimed to evaluate the clinical impact of molecular point-of-care testing (mPOCT) for gastrointestinal pathogens in patients with suspected gastroenteritis. The results showed that mPOCT could return results more quickly and reduce the use of single-occupancy rooms.
LANCET INFECTIOUS DISEASES
(2023)
Review
Chemistry, Analytical
Alexandar Todorov, Russel Torah, Michael R. Ardern-Jones, Steve P. Beeby
Summary: Atopic dermatitis (AD) is a prevalent skin disorder, particularly in children and adolescents, with current assessment methods relying on visual examination by clinicians. However, this approach is subjective and limited. Digital sensing technologies offer a potential solution for accurate and empirical evaluation of AD, allowing for global access. This review focuses on current medical practices, alternative digital evaluation methods, and potential future technologies to develop an AD monitoring device.
Article
Multidisciplinary Sciences
Sofia Sirvent, Andres F. Vallejo, Emma Corden, Ying Teo, James Davies, Kalum Clayton, Eleanor G. Seaby, Chester Lai, Sarah Ennis, Rfeef Alyami, Gemma Douilhet, Lareb S. N. Dean, Matthew Loxham, Sarah Horswill, Eugene Healy, Graham Roberts, Nigel J. Hall, Peter S. Friedmann, Harinder Singh, Clare L. Bennett, Michael R. Ardern-Jones, Marta E. Polak
Summary: Regulation of cutaneous immunity is compromised in inflammatory skin disease, such as atopic dermatitis. A study investigating molecular crosstalk in atopic dermatitis patients exposed to house dust mite has revealed a distinct dichotomy in patient responsiveness and identified potential therapeutic targets for modulation of metallothionein expression. The presence of hub structures where Langerhans cells and T cells co-localize suggests their role in the reactivity to house dust mite.
NATURE COMMUNICATIONS
(2023)
Review
Dermatology
Margo Waters, Allison Dobry, Stephanie T. Le, Kanade Shinkai, Thomas M. Beachkofsky, Mark D. P. Davis, Arturo R. Dominguez, Daniela Kroshinsky, Alina Markova, Robert G. Micheletti, Arash Mostaghimi, Helena B. Pasieka, Misha Rosenbach, Lucia Seminario-Vidal, John Trinidad, Joerg Albrecht, Emily M. Altman, Ryan Arakaki, Michael Arden-Jones, Alina G. Bridges, Adela R. Cardones, Angad A. Chadha, Jennifer K. Chen, Steven T. Chen, Kyle Cheng, Steven Daveluy, Katherine L. DeNiro, Joanna Harp, Jesse J. Keller, Brett King, Abraham M. Korman, Eve J. Lowenstein, Erin Luxenberg, Jennifer Brescoll Mancuso, Melissa M. Mauskar, Philip Milam, Kiran Motaparthi, Caroline A. Nelson, Cuong V. Nguyen, Fnu Nutan, Alex G. Ortega-Loayza, Tejesh Patel, Sahand Rahnama-Moghadam, Sergey Rekhtman, Nathan W. Rojek, Mansi Sarihan, Sheila Shaigany, Timmie R. Sharma, Sabrina M. Shearer, Bridget E. Shields, Lindsay C. Strowd, Danielle M. Tartar, Cristina Thomas, Karolyn A. Wanat, Andrew C. Walls, Lisa C. Zaba, Carolyn M. Ziemer, Emanual Maverakis, Benjamin H. Kaffenberger
Summary: This article discusses the importance of developing a skin-directed scoring system for EN, including consistent terminology and morphologic traits, as well as identifying the most affected sites. Through a Delphi consensus exercise, it was determined that there is a need for a skin-directed scoring system for EN.
Article
Gastroenterology & Hepatology
Mohammed Nabil Quraishi, Elizabeth Dobson, Rachel Ainley, Shahida Din, Ruth Wakeman, Fraser Cummings, Shaji Sebastian, Stuart Bloom, Jimmy K. Limdi, Anjan Dhar, R. Alexander Speight, Keith Bodger, Nicholas A. Kennedy, Christopher A. Lamb, Ian D. Arnott, Christian P. Selinger
Summary: This study establishes key performance indicators (KPIs) for benchmarking the quality of care for patients with inflammatory bowel disease (IBD) in the UK. These KPIs were determined through stakeholder meetings and a Delphi consensus process, and aim to improve and reduce variation in IBD care.
FRONTLINE GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Gerum G. Gebeyehu, Frederick Taylor, Liz Dobson, J. R. Fraser Cummings, Stuart Bloom, Nicholas A. Kennedy, Paul Christiansen, Keith Bodger
Summary: The IBD-Control-8 is a psychometrically robust scale that can be used in various populations. It offers a quick, reliable, and valid method for assessing patient-perceived control.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Medicine, Research & Experimental
Ran Jin, Chidozie Nduka, Delphine Courmier, Hannah Knight, Rachael Meadows, James Piercy, J. R. F. Cummings, Waldemar Radziszewski
Summary: The use of ABP 501 biosimilar in the treatment of inflammatory bowel disease has shown positive outcomes and high satisfaction among patients.
ADVANCES IN THERAPY
(2023)